Incyte Receives EU Approval for Zynyz in New Indication
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy INCY?
Source: NASDAQ.COM
- New Indication Approval: Incyte announced that its drug Zynyz (retifanlimab) in combination with carboplatin and paclitaxel has received approval from the European Commission for the treatment of metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC), marking the second indication for the drug in Europe.
- Clinical Trial Support: This approval is supported by data from the Phase 3 POD1UM-303/InterAACT2 trial, which evaluated the efficacy of Zynyz versus placebo in combination with carboplatin and paclitaxel, demonstrating significant effectiveness in adult patients who had not previously received systemic chemotherapy.
- Market Potential Expansion: Zynyz is also approved as a monotherapy for the first-line treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S., EU, Canada, and Switzerland, providing Incyte with broader market opportunities and enhancing its competitive position in oncology.
- Stock Price Dynamics: Incyte's stock closed at $95.94 on March 6, down $1.39 (1.43%), and slipped further to $95.40 in after-hours trading, indicating a cautious market reaction to the news.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCY
Wall Street analysts forecast INCY stock price to rise
19 Analyst Rating
9 Buy
9 Hold
1 Sell
Moderate Buy
Current: 97.100
Low
73.00
Averages
100.31
High
125.00
Current: 97.100
Low
73.00
Averages
100.31
High
125.00
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Incyte Receives EU Approval for Zynyz in New Indication
- New Indication Approval: Incyte announced that its drug Zynyz (retifanlimab) in combination with carboplatin and paclitaxel has received approval from the European Commission for the treatment of metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC), marking the second indication for the drug in Europe.
- Clinical Trial Support: This approval is supported by data from the Phase 3 POD1UM-303/InterAACT2 trial, which evaluated the efficacy of Zynyz versus placebo in combination with carboplatin and paclitaxel, demonstrating significant effectiveness in adult patients who had not previously received systemic chemotherapy.
- Market Potential Expansion: Zynyz is also approved as a monotherapy for the first-line treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S., EU, Canada, and Switzerland, providing Incyte with broader market opportunities and enhancing its competitive position in oncology.
- Stock Price Dynamics: Incyte's stock closed at $95.94 on March 6, down $1.39 (1.43%), and slipped further to $95.40 in after-hours trading, indicating a cautious market reaction to the news.
See More
FDA Rejects Zynyz's Additional Indication Application
- FDA Rejection: The U.S. FDA has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte and MacroGenics, primarily due to compliance issues at a third-party manufacturing site operated by Novo Nordisk's Catalent unit, highlighting the stringent regulatory environment for drug approvals.
- Complete Response Letter: Incyte noted in its regulatory filing that the FDA issued a Complete Response Letter, citing Catalent Indiana's compliance as the sole approvability issue, which indicates that other aspects were not questioned, potentially providing hope for future applications.
- Clinical Trial Support: The supplemental Biologics License Application (sBLA) was supported by data from the company's Phase 3 POD1UM-304 trial, aiming to provide a combination therapy of antibody treatment and chemotherapy for adults with metastatic non-small cell lung cancer, showcasing the drug's potential market value.
- EU Approval Progress: Despite the FDA's rejection of the new indication application, Incyte simultaneously announced that Zynyz has received EU approval as a first-line treatment option for adults with SCAC, indicating that the drug still holds growth potential in international markets.
See More
Incyte's Zynyz Drug Receives EU Approval for Rare Cancer
- Drug Approval: Incyte announced that its Zynyz drug has received approval from the European Commission for another rare cancer, marking the drug's second approval in the region and demonstrating the company's ongoing innovation in rare disease treatment.
- Indication Expansion: The approval allows Zynyz to be used in combination with carboplatin and paclitaxel for adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal, further broadening its clinical application scope.
- Market Potential: Zynyz was previously approved in Europe for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma, indicating its potential market value across multiple cancer treatments, which could lead to significant revenue growth for Incyte.
- Strategic Implications: This approval not only enhances Incyte's competitiveness in oncology but may also attract more investor interest in its R&D pipeline, further solidifying the company's position in the biopharmaceutical industry.
See More
Zynyz Approved by EU for Advanced SCAC Treatment
- First Systemic Treatment: Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel has become the first systemic treatment for adult patients with advanced squamous cell carcinoma of the anal canal (SCAC) in Europe, marking a significant advancement in treatment options.
- Clinical Trial Results: The POD1UM-303 study demonstrated that the median progression-free survival (PFS) for the Zynyz combination group was 9.3 months, significantly better than the 7.4 months in the control group, indicating a 37% reduction in the risk of progression or death (P=0.0006), providing new hope for patients.
- Safety Analysis: Among patients receiving Zynyz in combination with chemotherapy, 47% experienced serious adverse reactions, primarily sepsis and pulmonary embolism; however, the safety profile was consistent with other PD-1 inhibitors combined with chemotherapy, with no new safety signals identified.
- Market Outlook: This approval represents the second indication for Zynyz in Europe and further solidifies Incyte's leadership in the field of tumor immunotherapy, expected to drive growth in this rare cancer market.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Positive Opinion for Olumiant in Treating Severe Alopecia Areata in Adolescents
- Clinical Trial Results: The Phase 3 BRAVE-AA-PEDS study demonstrated that 42% of patients with severe alopecia areata achieved over 80% scalp hair coverage at 36 weeks, indicating Olumiant's efficacy in adolescents and potentially providing a new treatment option for this vulnerable population.
- Regulatory Progress: The European Medicines Agency (EMA) has issued a positive opinion for Olumiant's use in treating severe alopecia areata in adolescents aged 12 to under 18, with a final decision expected in the next one to two months, further facilitating market access for the drug.
- Significant Treatment Effects: The study revealed that 36.5% of patients achieved near-complete scalp hair regrowth within 36 weeks, with 50% experiencing successful eyebrow regrowth and 42.9% achieving eyelash regrowth, highlighting its potential to improve patients' quality of life.
- Broad Market Prospects: As the first JAK inhibitor approved by both EMA and FDA for adult severe alopecia areata, the expansion of Olumiant's application to adolescents will further solidify Lilly's leadership in the treatment of autoimmune diseases, addressing the urgent market demand for effective therapeutic options.
See More
Incyte Receives EU Approval for Zynyz in New Indication
- New Indication Approval: Incyte announced that its drug Zynyz (retifanlimab) in combination with carboplatin and paclitaxel has received approval from the European Commission for the treatment of metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC), marking the second indication for the drug in Europe.
- Clinical Trial Support: This approval is supported by data from the Phase 3 POD1UM-303/InterAACT2 trial, which evaluated the efficacy of Zynyz versus placebo in combination with carboplatin and paclitaxel, demonstrating significant effectiveness in adult patients who had not previously received systemic chemotherapy.
- Market Potential Expansion: Zynyz is also approved as a monotherapy for the first-line treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S., EU, Canada, and Switzerland, providing Incyte with broader market opportunities and enhancing its competitive position in oncology.
- Stock Price Dynamics: Incyte's stock closed at $95.94 on March 6, down $1.39 (1.43%), and slipped further to $95.40 in after-hours trading, indicating a cautious market reaction to the news.
See More
FDA Rejects Zynyz's Additional Indication Application
- FDA Rejection: The U.S. FDA has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte and MacroGenics, primarily due to compliance issues at a third-party manufacturing site operated by Novo Nordisk's Catalent unit, highlighting the stringent regulatory environment for drug approvals.
- Complete Response Letter: Incyte noted in its regulatory filing that the FDA issued a Complete Response Letter, citing Catalent Indiana's compliance as the sole approvability issue, which indicates that other aspects were not questioned, potentially providing hope for future applications.
- Clinical Trial Support: The supplemental Biologics License Application (sBLA) was supported by data from the company's Phase 3 POD1UM-304 trial, aiming to provide a combination therapy of antibody treatment and chemotherapy for adults with metastatic non-small cell lung cancer, showcasing the drug's potential market value.
- EU Approval Progress: Despite the FDA's rejection of the new indication application, Incyte simultaneously announced that Zynyz has received EU approval as a first-line treatment option for adults with SCAC, indicating that the drug still holds growth potential in international markets.
See More
Incyte's Zynyz Drug Receives EU Approval for Rare Cancer
- Drug Approval: Incyte announced that its Zynyz drug has received approval from the European Commission for another rare cancer, marking the drug's second approval in the region and demonstrating the company's ongoing innovation in rare disease treatment.
- Indication Expansion: The approval allows Zynyz to be used in combination with carboplatin and paclitaxel for adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal, further broadening its clinical application scope.
- Market Potential: Zynyz was previously approved in Europe for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma, indicating its potential market value across multiple cancer treatments, which could lead to significant revenue growth for Incyte.
- Strategic Implications: This approval not only enhances Incyte's competitiveness in oncology but may also attract more investor interest in its R&D pipeline, further solidifying the company's position in the biopharmaceutical industry.
See More
Zynyz Approved by EU for Advanced SCAC Treatment
- First Systemic Treatment: Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel has become the first systemic treatment for adult patients with advanced squamous cell carcinoma of the anal canal (SCAC) in Europe, marking a significant advancement in treatment options.
- Clinical Trial Results: The POD1UM-303 study demonstrated that the median progression-free survival (PFS) for the Zynyz combination group was 9.3 months, significantly better than the 7.4 months in the control group, indicating a 37% reduction in the risk of progression or death (P=0.0006), providing new hope for patients.
- Safety Analysis: Among patients receiving Zynyz in combination with chemotherapy, 47% experienced serious adverse reactions, primarily sepsis and pulmonary embolism; however, the safety profile was consistent with other PD-1 inhibitors combined with chemotherapy, with no new safety signals identified.
- Market Outlook: This approval represents the second indication for Zynyz in Europe and further solidifies Incyte's leadership in the field of tumor immunotherapy, expected to drive growth in this rare cancer market.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Positive Opinion for Olumiant in Treating Severe Alopecia Areata in Adolescents
- Clinical Trial Results: The Phase 3 BRAVE-AA-PEDS study demonstrated that 42% of patients with severe alopecia areata achieved over 80% scalp hair coverage at 36 weeks, indicating Olumiant's efficacy in adolescents and potentially providing a new treatment option for this vulnerable population.
- Regulatory Progress: The European Medicines Agency (EMA) has issued a positive opinion for Olumiant's use in treating severe alopecia areata in adolescents aged 12 to under 18, with a final decision expected in the next one to two months, further facilitating market access for the drug.
- Significant Treatment Effects: The study revealed that 36.5% of patients achieved near-complete scalp hair regrowth within 36 weeks, with 50% experiencing successful eyebrow regrowth and 42.9% achieving eyelash regrowth, highlighting its potential to improve patients' quality of life.
- Broad Market Prospects: As the first JAK inhibitor approved by both EMA and FDA for adult severe alopecia areata, the expansion of Olumiant's application to adolescents will further solidify Lilly's leadership in the treatment of autoimmune diseases, addressing the urgent market demand for effective therapeutic options.
See More
